Pharmaceutical companies including Pfizer and Bristol-Myers Squibb Co. have spent the last several years digesting earlier acquisitions, refocusing their product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they're ready to start buying other companies again.
Pharma deals north of $10 billion seen returning in 2013
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You